EGFR-TKI, Cardiac adverse events, Cardiotoxicity, Targeted therapies, Pharmacovigilance analysis
Neoadjuvant therapy, chemoradiotherapy, immunochemoradiotherapy, oesophageal squamous cell carcinoma, survival